Introduction
Ceftaroline fosamil (hereafter referred to as 'ceftaroline') is a new parenterally administered cephalosporin that is rapidly converted by plasma phosphatases into active ceftaroline following intravenous (iv) administration. Ceftaroline exhibits an expanded spectrum of activity compared with other cephalosporins, with bactericidal activity against resistant Gram-positive organisms, such as drug-resistant Streptococcus pneumoniae and methicillinresistant Staphylococcus aureus (MRSA), while maintaining the familiar safety profile consistent with this class. 1 -5 The cephalosporin class of antimicrobial agents remains the most frequently prescribed class of antimicrobials in the USA and worldwide. 6 -11 Since the first discovery of the cephalosporins in the mid-20th century, 12 the class has maintained a favourable record of safety and tolerability 13 with exception only for those cephalosporins that contain a methylthiotetrazole side chain (i.e. cefamandole, cefmetazole, cefoperazone, cefotetan and moxalactam), which inhibits activation of vitamin K-dependent clotting factors via inhibition of vitamin K epoxide reductase. 14, 15 The adverse events (AEs) reported with various cephalosporin derivatives are similar. Oral formulations are associated with gastrointestinal (GI) effects (e.g. diarrhoea, nausea and vomiting), headache and rash. AEs associated with parenteral cephalosporins include local reactions at the injection site, GI effects and adverse haematological effects. Hypersensitivity reactions to cephalosporins have been reported in 5% or fewer patients, and 10% -15% of patients with a history of penicillin hypersensitivity may have a cross-sensitivity reaction to cephalosporins. 16 Current guidelines for the treatment of community-acquired pneumonia (CAP) in the USA recommend a respiratory fluoroquinolone or a b-lactam plus a macrolide as empirical therapy for non-intensive care unit inpatient or hospitalized patients with CAP. 17 Respiratory fluoroquinolones are effective in the treatment of CAP; however, these agents have been associated with potentially treatment-limiting adverse effects such as tendon rupture and cardiac QT prolongation. 18, 19 Additional agents as empirical therapy are recommended when Pseudomonas or community-acquired MRSA is suspected, such as vancomycin or linezolid for MRSA. 17 Unfortunately, treatment-restricting adverse effects, such as nephrotoxicity requiring vancomycin drug level and renal function monitoring, 20, 21 linezolid-associated myelosuppression 22, 23 or drug interactions 24, 25 may limit the utility of these agents. More therapeutic options are needed for clinicians trying to choose the best therapy for the management of CAP. This is evidenced by the recent Infectious Diseases Society of America (IDSA) campaign for approval of new safe and effective antimicrobial agents in light of emerging resistance among organisms for many types of infections. 26 Furthermore, additional antimicrobial options are needed to ensure the future safety of patients in healthcare institutions. Any reduction in the widespread use of combination therapy or inappropriate use of broader-spectrum coverage than needed for indications such as CAP and complicated skin and skin structure infections (cSSSIs) will help to lessen the potential for resistance development. Using empirical broad-spectrum agents with activity against organisms such as Pseudomonas and Acinetobacter spp. for the treatment of infections that typically do not include these pathogens as part of their differential diagnosis has the potential to cultivate resistant nosocomial pathogens within institutions, which would adversely impact patient safety in the future. Additionally, delays in appropriate antimicrobial therapy may correlate with increased morbidity and mortality. 27, 28 There is a clear need for empirical agents that specifically target the pathogens most likely to be responsible for CAP.
Ceftaroline has been evaluated for the treatment of moderate to severe bacterial infections in four Phase III clinical trials; two in cSSSIs and two in CAP, which are the focus of this article. 1,29 -31 This report provides an integrated safety summary of the ceFtarOline Community-acquired pneUmonia trial versuS ceftriaxone (FOCUS) 1 and 2 trials (registration numbers: NCT00621504 and NCT00509106), which evaluated the safety and efficacy of 600 mg of ceftaroline administered iv every 12 h compared with 1 g of ceftriaxone administered iv every 24 h in adult patients with CAP.
Methods
The FOCUS 1 and 2 trials were designed as parallel, methodologically identical (with the exception of two doses of the short-acting macrolide, clarithromycin, administered on day 1 in FOCUS 1), double-blind, randomized, multicentre, comparative studies to evaluate the safety and efficacy of 600 mg of ceftaroline administered iv every 12 h versus 1 g of ceftriaxone administered iv every 24 h in patients with CAP for 5-7 days without allowing a switch to commercially available oral medications to complete therapy. Details of the study design and integrated results for these two studies were described previously, 29 and efficacy results for the individual FOCUS 1 and FOCUS 2 trials are reported elsewhere in this supplement. 30, 31 This report provides an integrated safety summary of the FOCUS 1 and 2 trials.
A total of 1228 patients received any amount of study drug and were included in the safety population for the two FOCUS trials (613 in the ceftaroline group and 615 in the ceftriaxone group). All patients who entered into the FOCUS trials were to meet eligibility criteria and provided informed consent after the risks and requirements of the study had been explained. A baseline history and physical examination, including radiographic evaluation with chest X-ray or CT of the chest, were performed. At baseline, urine for urinalysis and blood for a complete blood count (CBC), direct antiglobulin test, serum chemistry panel and other laboratory measurements were obtained. Patients were randomized in a blinded fashion to receive iv ceftaroline or iv ceftriaxone for 5 -7 days. All patients were followed for AEs occurring from the start of the initial study drug infusion up to the test-of-cure (TOC) visit, 1 week following the last dose of study medication; all AEs were followed until resolution or stabilization. All AEs were recorded on case report forms and assessed for degree of severity and relationship to study drug by the investigator (MedDRA Version 11.1). Severity and relatedness were summarized as incidences based on the worst severity rating or the greatest degree of relatedness observed when a patient had more than one treatment-emergent AE (TEAE) of the same term.
Regardless of the investigator's assessment of the relationship to study drug, any AEs resulting in death, inpatient hospitalization or prolongation of existing hospitalization, a potentially life-threatening event, a persistent or significant disability or incapacity, a congenital anomaly or birth defect in the offspring of a patient who received study drug, or which adversely altered the patient's physiological state of health such that medical or surgical intervention may have been required, was considered a serious adverse event (SAE). All SAEs were recorded up to the late follow-up (LFU) visit or 30 days after the last dose of study drug; all SAEs were followed until resolution. AEs were considered TEAEs when the onset occurred or severity worsened on or after the first dose of study drug. Urinalysis, CBCs and serum chemistries were repeated at the end-of-therapy (EOT) and at the TOC visits, or at any time during the study, as deemed necessary by the investigator.
Results
The demographic and baseline characteristics of patients in the ceftaroline and ceftriaxone groups were well balanced with respect to all aspects evaluated, including race, gender, age, baseline renal function, Pneumonia Outcomes Research Team (PORT) risk class and the presence or absence of underlying structural lung disease (Table 1) . Thus, the comparative distribution of AEs between the ceftaroline and the ceftriaxone groups was unlikely to be confounded by demographic characteristics within treatment groups. Furthermore, mean exposure to study drug was the same between the ceftaroline and ceftriaxone groups (6.5+1.1 days). The percentages of patients who had at least one TEAE (47.0% versus 45.7%), SAE (11.3% versus 11.7%), discontinuation due to an AE (4.4% versus 4.1%) or who died (2.4% versus 2.0%) were similar between the ceftaroline and ceftriaxone groups, respectively.
There were 27 deaths during the FOCUS trials, with 15 occurring in the ceftaroline group and 12 in the ceftriaxone group (Table 2) . Two deaths (one in each treatment group) were assessed by the investigator as possibly related to study drug. One was noted in a 73-year-old female smoker in the ceftaroline group who had premature atrial complexes on a baseline electrocardiogram (ECG) and was found unresponsive on the third day of the study. Resuscitation was unsuccessful and no laryngeal oedema or difficulty with intubation was noted. The cardiologist suspected the patient died of a myocardial infarction, but no autopsy was performed. The other was a patient in the ceftriaxone group with multiorgan failure following possible drug-induced liver injury. The individual terms for SAEs leading to death were generally similar between the ceftaroline and ceftriaxone groups with the exception of the terms: 'sudden death' (two versus zero, respectively) and terms representing underlying neoplasms (four versus zero, respectively). A review of all deaths in the FOCUS trials revealed that three patients in the ceftaroline group and four patients in the ceftriaxone group died of sudden events; however, for one patient in the ceftaroline group and four patients in the ceftriaxone group the aetiology of death was not recorded by the investigator as a 'sudden death' because the death was either presumed to be caused by 'acute cardiac failure', 'cardiac arrest' or 'cardiopulmonary failure' or, in one instance, the patient had an autopsyconfirmed diagnosis of a 'pulmonary embolism'. Likewise, although no patient's death in the ceftriaxone group was attributed to an underlying neoplastic process by the investigator, one ceftriaxone-treated patient had underlying mesothelioma and diffuse pulmonary microemboli (to which death was attributed) discovered at autopsy.
A review of SAEs revealed no patterns or safety signals, and 95.7% (66/69) of the SAEs in the ceftaroline group and 91.7% (66/72) in the ceftriaxone group were assessed by the investigator as unrelated to study drug. Only seven SAEs occurred in more than two patients in the ceftaroline group. These SAEs were pneumonia (worsening or relapse of CAP or nosocomial pneumonia; nine versus nine), pleural effusion (five versus six), pulmonary embolism (five versus four), chronic obstructive pulmonary disease (four versus six), pyothorax (four versus zero), respiratory failure (four versus one) and malignant lung neoplasm (three versus zero) in the ceftaroline group versus the ceftriaxone group, respectively. TEAEs resulting in discontinuation of study drug or withdrawal from the study (occurring in more than one patient in either treatment group) are summarized in Table 3 . No TEAE in the ceftaroline group led to discontinuation Creatinine clearance (mL/min), a n (%)
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iii55 JAC of study drug or withdrawal from study in more than two patients. In general, the most common SAEs and the most common TEAEs leading to discontinuation represented insufficient therapeutic effect resulting in prolonged hospitalization (one of the criteria meeting the definition of an SAE) or represented AEs that led to death (resulting in withdrawal from the study). Table 4 describes AEs seen in either treatment group with a frequency of .1% and in which a difference of at least 0.5% was observed between ceftaroline and ceftriaxone. Diarrhoea, headache and insomnia were the most common of these AEs occurring in 3%-4% of patients in the ceftaroline group. All AEs were graded based on severity (by the investigator) as mild, moderate or severe. In the ceftaroline and ceftriaxone groups, AEs were generally mild or moderate, with the distribution of patients with AEs for each severity category being similar between treatment groups. Most patients had no TEAE (53.0% versus 54.3%) or mild TEAEs (24.5% versus 20.0%) in the ceftaroline and ceftriaxone groups, respectively; 16.2% of ceftaroline-treated patients and 18.4% of ceftriaxonetreated patients had moderate TEAEs. Severe TEAEs were reported in 6.4% of ceftaroline-treated and 7.3% of ceftriaxonetreated patients. Table 5 summarizes renal events (elevations in serum creatinine, decreases in creatinine clearance and/or renal TEAEs) observed during the FOCUS trials. Overall, similar percentages of patients in the ceftaroline and ceftriaxone groups had any renal event (2.9% versus 2.4%, respectively), elevated serum creatinine levels (2.0% versus 1.7%, respectively), decreased creatinine clearance (1.0% versus 1.5%, respectively) or renal TEAEs (1.6% versus 0.8%, respectively).
Hepatic TEAEs are presented in Table 6 . Fewer ceftarolinetreated patients had at least one TEAE referable to the hepatic system compared with ceftriaxone-treated patients. Although minor elevations in liver function tests are difficult to interpret and may not be considered significant, evaluating patterns of various liver function tests together can provide a more meaningful prediction of hepatocellular toxicity. Increases in multiples of the upper limit of normal (ULN) for various liver function tests are shown in Table 7 (irrespective of whether or not the investigator considered the abnormality a TEAE). There was no difference between treatment groups in the percentage of patients observed to have 3-or 5-fold increases above the ULN for both aspartate aminotransferase (AST) and alanine aminotransferase (ALT). A more sensitive predictor for possible drug-induced hepatocellular damage is indicated by an increase in ALT or AST 3-fold above the ULN, a ,2-fold increase in alkaline phosphatase, plus One led to discontinuation of study drug and one led to withdrawal from study. An individual patient may have more than one renal TEAE reported. a .2-fold increase in bilirubin above the ULN occurring simultaneously in an individual patient. 32 These criteria (referred to as Hy's Law laboratory criteria) were not observed in any patient in the ceftaroline group and were observed in one patient in the ceftriaxone group who had underlying cholecystitis.
Additional TEAEs in the FOCUS trials were reviewed because of their known association with b-lactams or with other antibacterial classes and are summarized below. Diarrhoea was the most common of these AEs in both treatment groups, with an incidence of 4.2% in the ceftaroline group compared with 2.6% in the ceftriaxone group. Although Clostridium difficile testing was not required as part of the study procedures, no patient had C. difficile reported in either treatment group during the FOCUS trials. Potential allergic reactions were uncommon in the ceftaroline and ceftriaxone groups (1.5% versus 1.6%, respectively), and only one was reported as an SAE (hypersensitivity, in the ceftriaxone group).
In the FOCUS trials, 9.8% of ceftaroline-treated patients and 4.5% of ceftriaxone-treated patients tested experienced a direct antiglobulin test seroconversion from negative baseline result to a positive result. An extensive review of patients with an AE and/or laboratory abnormalities suggestive of anaemia or haemolysis did not reveal any patient with a presentation consistent with haemolytic anaemia (Table 8) . One patient in each treatment group had an AE of seizure. Similar numbers of patients in the ceftaroline and the ceftriaxone groups (six compared with five, respectively) experienced a prolongation of the QTcB interval (QTcB .500 ms and a change from baseline of ≥60 ms).
Discussion
In this summary of the integrated FOCUS safety data, no unexpected safety concerns for ceftaroline were noted in the .1200 patients evaluated. Both ceftaroline and ceftriaxone were well tolerated, and the incidences of TEAEs, SAEs, discontinuations and deaths were similar between groups. The small numerical disparity in patients who died appears to represent an imbalance in underlying neoplastic processes likely to have been present at baseline because the deaths related to neoplastic processes in the FOCUS trials would not be expected to be attributable to ceftaroline given the short duration of treatment of ≤7 days, a maximum follow-up period of 5 weeks posttherapy and a lack of any in vitro or in vivo non-clinical evidence of mutagenicity. 33 -42 The majority of patients in the FOCUS studies ( 75%) had either no TEAEs or only mild TEAEs, and the distribution of TEAEs based on severity was comparable between ceftaroline and ceftriaxone. The most common AEs shown in Table 4 are consistent with those described in association with other cephalosporins. 13 In the FOCUS trials, the most commonly reported TEAEs in patients treated with ceftaroline included diarrhoea, headache and insomnia. None of the potential antibioticassociated diarrhoea from either treatment group in the FOCUS trials was attributable to C. difficile. These results suggest that ceftaroline has little impact on the intestinal microflora and low risk for development of C. difficile infection. This may be supported by data from a study of 12 healthy adults who received 600 mg of ceftaroline every 12 h for 7 days, in which ceftaroline was found to be absent in faecal samples and no new aerobic or anaerobic colonizing strains with ceftaroline MICs of ≥4 mg/L were found post-administration. 43 Although small numbers of patients in both treatment groups had renal and/or hepatic dysfunction during the FOCUS trials, no indication of clinically meaningful differences in potential renal or hepatocellular damage was observed between ceftaroline and ceftriaxone. Approximately 1%-3% of the population may develop allergic skin reactions to cephalosporins, 44, 45 and similar or lower rates were noted for ceftaroline in the FOCUS trials. The incidence of direct antiglobulin seroconversion (positive Coombs' test) was greater with ceftaroline compared with ceftriaxone; however, no patient in either treatment group was identified with a clinical presentation consistent with haemolytic anaemia. Although Number of subjects with a baseline and more than one post-dose assessment, with the exception of direct antiglobulin (Coombs'), for which subjects had both a negative baseline assessment and more than one post-dose assessment. Integrated safety summary of FOCUS 1 and 2
iii57 JAC cephalosporins (including ceftriaxone) are rarely associated with haemolytic anaemia, there is no clear association between the incidence of direct antiglobulin seroconversion and the relative risk of haemolytic anaemia. 13,46 -49 In a separate thorough ECG trial with moxifloxacin as a positive control, there was no observable effect on the QT interval following administration of a single dose of 1500 mg of ceftaroline. 50 These data and the similar incidence of a prolonged QTcB interval with ceftaroline compared with ceftriaxone therapy in the FOCUS trials suggest a lack of any clinically meaningful effect on cardiac repolarization by ceftaroline therapy.
The data from previous clinical trials 2 and from the FOCUS trials 30, 31 suggest that ceftaroline retains the desirable safety and tolerability profile that is expected of agents in this class. Adverse effects and laboratory findings from the FOCUS trials were consistent with those seen with other drugs in the cephalosporin class. No clinically significant safety concerns have been identified with ceftaroline. Therefore, based on the safety and tolerability profile of ceftaroline from the integrated FOCUS analysis, as well as its efficacy (described separately in this Supplement), ceftaroline should prove to be a useful addition to the armamentarium of antimicrobial agents available to clinicians for the treatment of CAP.
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